慢性阻塞性肺疾病药物治疗:美国胸科学会官方临床实践指南
该指南由美国胸科学会组织COPD专家与方法学家,系统评价证据后采用GRADE方法形成推荐。主要推荐包括:对有呼吸困难或运动不耐受的COPD患者,强烈推荐LABA/LAMA联合优于单药;对过去一年有≥1次急性加重者,条件推荐ICS/LABA/LAMA三联优于LABA/LAMA双联;对三联治疗且过去一年无急性加重者,条件推荐撤除ICS;对血嗜酸性粒细胞增多者,除有急性加重史需抗生素/口服激素/住院外,不推荐也不反对加用ICS;条件推荐反对维持口服激素,条件推荐阿片类治疗难治性呼吸困难。
要点
- 呼吸困难或运动不耐受的COPD患者,强烈推荐LABA/LAMA联合治疗优于单药治疗。
- 过去一年有≥1次急性加重的COPD患者,条件推荐三联疗法优于LABA/LAMA双联。
- 三联治疗且过去一年无急性加重者,条件推荐撤除ICS;血嗜酸性粒细胞增多者需个体化评估。
核心结论
- 指南基于现有证据对COPD药物治疗做出推荐,并指出需在80岁以上、多重慢病及COPD合并哮喘人群中进一步研究。
研究设计与样本
- 由美国胸科学会组织COPD专家与方法学家组成专家组,对相关研究进行系统证据合成,采用GRADE方法评估证据并形成推荐。
主要发现
- 对呼吸困难或运动不耐受的COPD患者,强烈推荐LABA/LAMA联合优于LABA或LAMA单药。
- 对过去一年有≥1次急性加重的呼吸困难或运动不耐受患者,条件推荐ICS/LABA/LAMA三联优于LABA/LAMA双联。
- 对接受三联治疗且过去一年无急性加重的患者,条件推荐撤除ICS。
- 对血嗜酸性粒细胞增多的COPD患者,除过去一年有≥1次需抗生素或口服激素或住院的急性加重外,不推荐也不反对加用ICS;有上述急性加重史者条件推荐加用ICS。
- 对有严重频繁急性加重史的COPD患者,条件推荐反对维持口服激素;对优化治疗后仍难治性呼吸困难者,条件推荐阿片类治疗。
关键数值与推荐
- 强烈推荐:LABA/LAMA联合优于单药,适用于有呼吸困难或运动不耐受的COPD患者。
- 条件推荐:ICS/LABA/LAMA三联优于LABA/LAMA双联,适用于过去一年有≥1次急性加重的呼吸困难或运动不耐受患者。
- 条件推荐:撤除ICS,适用于接受三联治疗且过去一年无急性加重的患者。
- 条件推荐:加用ICS,适用于血嗜酸性粒细胞增多且过去一年有≥1次需抗生素或口服激素或住院的急性加重患者;其余血嗜酸性粒细胞增多者不推荐也不反对。
- 条件推荐:反对维持口服激素用于有严重频繁急性加重史者;条件推荐阿片类用于优化治疗后仍难治性呼吸困难者。
临床怎么用
- 对呼吸困难或运动不耐受的COPD患者,优先考虑LABA/LAMA联合治疗而非单药。
- 对过去一年有急性加重且症状明显的患者,可考虑三联疗法;无急性加重者考虑撤除ICS。
- 血嗜酸性粒细胞增多者需结合急性加重史决定是否加用ICS,避免常规维持口服激素。
局限性
- 证据在80岁及以上、多重慢病及COPD合并哮喘人群中不足,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: This document provides clinical recommendations for the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative effort on the part of a panel of expert COPD clinicians and researchers along with a team of methodologists under the guidance of the American Thoracic Society.Methods: Comprehensive evidence syntheses were performed on all relevant studies that addressed the clinical questions and critical patient-centered outcomes agreed upon by the panel of experts. The evidence was appraised, rated, and graded, and recommendations were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach.Results: After weighing the quality of evidence and balancing the desirable and undesirable effects, the guideline panel made the following recommendations: 1) a strong recommendation for the use of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy in patients with COPD and dyspnea or exercise intolerance; 2) a conditional recommendation for the use of triple therapy with inhaled corticosteroids (ICS)/LABA/LAMA over dual therapy with LABA/LAMA in patients with COPD and dyspnea or exercise intolerance who have experienced one or more exacerbations in the past year; 3) a conditional recommendation for ICS withdrawal for patients with COPD receiving triple therapy (ICS/LABA/LAMA) if the patient has had no exacerbations in the past year; 4) no recommendation for or against ICS as an additive therapy to long-acting bronchodilators in patients with COPD and blood eosinophilia, except for those patients with a history of one or more exacerbations in the past year requiring antibiotics or oral steroids or hospitalization, for whom ICS is conditionally recommended as an additive therapy; 5) a conditional recommendation against the use of maintenance oral corticosteroids in patients with COPD and a history of severe and frequent exacerbations; and 6) a conditional recommendation for opioid-based therapy in patients with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy.Conclusions: The task force made recommendations regarding the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are underrepresented in clinical trials is needed, including studies in patients with COPD 80 years of age and older, those with multiple chronic health conditions, and those with a codiagnosis of COPD and asthma.
引用
- Nici L, Mammen MJ, Charbek E, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020. PMID: 32283960. doi:10.1164/rccm.202003-0625ST
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。